Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today presented new, detailed results from the RELIEVE UCCD phase 2b study of duvakitug, a human IgG1-λ2 ...

Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug, a human IgG1-2 ...

French drug major Sanofi and the US unit of Israel’s Teva Pharmaceutical Industries have presented new, detailed results from the RELIEVE UCCD Phase IIb study of duvakitug, a human IgG1-λ2 monoclonal ...

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt® (CT-P42, aflibercept), a biosimilar to Eylea® to ...

Calgary Health Foundation is proud to announce the opening of Rockyview General Hospital's expanded endoscopy unit. The new Florence and Lloyd Cooper Endoscopy Unit was made possible thanks to $10M in ...

Aptose Biosciences Inc. ("Aptose” or the "Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company ...